Karl M. Kilgore, PhD | Authors


Evaluating the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

February 12, 2020

Karl M. Kilgore, PhD, discusses the role of chimeric antigen receptor T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and where this option might fit into the landscape in the future.